CASE STUDIES

Across all of these cases, the pattern is clear:

The pets who do best are not the ones who got lucky.

They are the ones whose owners:
→ tested early
→ acted proactively
→ stayed engaged in an ongoing strategy

That is the difference between standard care and longevity care.

And that is what we do at HelpingPetsLiveLonger.

_____________________

Case Study 1: Milo — Male Cat with Hypertrophic Cardiomyopathy (HCM)

Milo, a 6-year-old neutered male domestic shorthair, came to us through a proactive pet parent who “just wanted to be ahead of things.” Milo was eating well, playful, and showed no outward signs of illness. Like many cats, he appeared perfectly healthy.

But we know better.

As part of Milo’s Longevity Strategy Session, we recommended advanced functional bloodwork and cardiac screening, including NT-proBNP. His results showed early cardiac strain—well before any clinical signs. A follow-up echocardiogram confirmed early hypertrophic cardiomyopathy (HCM).

This is where most cats are missed.

HCM is often diagnosed only after a crisis—heart failure, thromboembolism, or sudden death. Milo’s diagnosis happened years earlier, when we still had time to intervene.

We initiated a targeted plan:

• Cardiac monitoring and blood pressure tracking
• Anti-inflammatory and metabolic support
• Longevity-focused supplementation
• Careful medication strategy based on progression

Most importantly, Milo’s parent now had a clear roadmap, not uncertainty.

Over the next 18 months, Milo has remained stable. No heart failure. No emergencies. No decline in quality of life.

He still chases toys. Still greets his owner at the door.

The difference?

We didn’t wait.

This is what early functional testing does. It shifts care from reaction to strategy.

And this is what a Longevity Strategy Session provides:
→ clarity
→ early detection
→ a plan that evolves over time

Milo’s story is not about curing HCM. It’s about changing the trajectory of the disease before it changes the pet’s life.

Case Study 2: Petunia — Female Cat with Early CKD

Petunia, a 12-year-old Persian, came to us for what her owner described as “just slowing down a little.” No vomiting. No weight loss. No obvious signs of kidney disease.

But we recommended deeper testing.

Her functional panel revealed:

• Early elevation in SDMA
• Mild hypertension
• Evidence of congenital polycystic kidney disease

Most importantly—this was Stage 1 CKD, long before traditional diagnostics would have flagged it.

We immediately implemented a comprehensive plan:

• Renal-supportive diet
• Blood pressure control
• Dental intervention (she had painful FORLs contributing to systemic inflammation)
• Rapamycin for anti-inflammatory and longevity support
• Longevity Plus and Transcend for mitochondrial and metabolic health

Three years later, Petunia is still thriving.

She jumps onto the sofa. Engages with her environment. Maintains her weight and appetite.

This is the power of early detection combined with ongoing strategy.

CKD is not a sudden disease. It is a slow, progressive decline that begins years before symptoms appear.

Most cats are diagnosed when 70% of kidney function is already lost.

Petunia was diagnosed when we could still make meaningful changes.

And just as important as the initial diagnosis is what came next:

• Regular monitoring
• Ongoing adjustments
• Direct access to Dr. Kevin for guidance

This is not one visit. This is a long-term relationship centered on optimization.

Petunia’s outcome wasn’t luck.

It was:
→ early testing
→ proactive intervention
→ consistent, expert oversight

Case Study 3: Max — Dog with Oral Melanoma -- Given 4 Months to Live

Max, a 10-year-old Golden Retriever, was diagnosed with oral melanoma after his owner noticed a small mass on his gum. By the time of diagnosis, the tumor was aggressive.

The prognosis from oncology:
4 months.

His owner came to us asking a simple question:
“Is there anything else we can do?”

The answer was yes—but it required a different approach.

We designed a comprehensive longevity protocol:

• Rapamycin to target cancer pathways and reduce tumor signaling
• Acarbose to blunt glucose spikes and limit metabolic fuel for cancer
• Longevity Plus to reduce systemic inflammation and support immune resilience
• Nutritional optimization and metabolic support

We also emphasized close monitoring and adaptive strategy, not a fixed plan.

Within months, Max stabilized.

His energy returned. Appetite improved. Tumor progression slowed.

But what happened next surprised everyone.

Max didn’t live 4 months.

He lived 3 more years.

Three years of walks. Three years of normal life. Three years his owner would not have had.

Was the cancer cured? No.

But the trajectory changed.

Cancer is not always a binary outcome. With the right interventions, we can often:
→ slow progression
→ improve quality of life
→ extend meaningful time

Max’s story reflects what is possible when we combine:

• Longevity pharmacology
• Metabolic strategy
• Continuous oversight

This is not standard care.

This is modern longevity medicine applied to cancer.

Case Study 4: Bella — Dog with Anal Gland Adenocarcinoma

Bella, a 9-year-old mixed breed, was diagnosed with anal gland adenocarcinoma after presenting with subtle changes in stool and mild lethargy.

By the time of diagnosis, the cancer had already begun to spread.

Her prognosis:
Approximately 6 months.

Her owner chose not to accept that timeline as fixed.

We initiated a combined approach:

• Rapamycin to modulate cancer growth pathways
• Metronomic chemotherapy to provide continuous low-dose anti-cancer pressure
• Anti-inflammatory and immune-supportive supplementation
• Close monitoring and frequent strategy adjustments

The goal was not just treatment—it was control over time.

Bella responded well.

Her energy returned. Her appetite stabilized. Her quality of life remained high.

Months passed. Then a year. Then two.

Today, three years later, Bella is still with us.

Still active. Still engaged. Still living a life her owner treasures.

This is the power of:
→ layered therapy
→ consistent oversight
→ refusing to treat prognosis as destiny

What made the difference?

Not a single intervention—but the combination:

• Longevity medicine
• Oncology strategy
• Ongoing access to Dr. Kevin

Bella’s care was never static. It evolved as her condition evolved.

And that is the key.

Case Study 5: Cooper — Labrador Retriever with Bilateral ACL Ruptures

Cooper, an 8-year-old Labrador, presented with progressive lameness. Imaging confirmed bilateral cruciate ligament ruptures—a devastating diagnosis for an active dog.

Surgery was discussed, but his owner wanted a broader plan.

We focused on:

• Rapamycin to reduce systemic inflammation and support tissue resilience
• Longevity Plus and Transcend for joint, mitochondrial, and metabolic health
• Structured rehabilitation and strengthening
• Regular laser therapy to reduce pain and improve healing

The goal was not just recovery—it was long-term joint preservation and function.

Over the next 6–12 months, Cooper improved steadily.

At 2 years post-diagnosis:

• He walks comfortably
• Maintains muscle mass
• Engages in moderate activity without pain

This outcome challenges the assumption that structural injury equals inevitable decline.

Instead, we approached Cooper as a whole-system patient:

• Inflammation
• metabolism
• tissue repair capacity

Most orthopedic cases focus on the joint.

We focus on the biology behind the joint.

Cooper’s success reflects what happens when:
→ longevity science meets rehab medicine
→ care is proactive and sustained
→ the plan is tailored, not generic

Case Study 6: Daisy — Female Dachshund with IVDD (No Surgery)

Daisy, a 7-year-old Dachshund, presented acutely with back pain and hind limb weakness—classic signs of intervertebral disc disease (IVDD).

Surgery was recommended.

Her owner declined.

Instead, we built a comprehensive non-surgical plan:

• Strict initial rest
• Targeted physical therapy
• Rapamycin to reduce inflammation and support neural recovery
• Long-term rehabilitation strategy

The key was precision and consistency.

Over weeks, Daisy improved.

Then months.

Today, she:

• Walks one mile daily
• Maintains mobility
• Lives without chronic pain

This is not typical—but it is possible with the right approach.

IVDD is not just a structural problem. It is:
→ inflammation
→ nerve injury
→ impaired recovery environment

By addressing all three, we change outcomes.

Daisy’s case highlights an important truth:

There is often more than one path forward.

And when guided correctly, non-surgical management can succeed.

But it requires:

• expert oversight
• structured rehab
• ongoing adjustment